Evidence map›Paper›PMID 31836719›Full record

ArticleScientific data2019

Engaging a community to enable disease-centric data sharing with the NF Data Portal.

Robert J Allaway, Salvatore La Rosa, Sharad Verma, Lara Mangravite, Justin Guinney, Jaishri Blakeley, Annette Bakker, Sara J C Gosline

Abstract read
In one paragraph

Article in Scientific data, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.Database : the journal of biological databases and curation · 2022
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robert J AllawaySage Bionetworks, Seattle, WA, 98146, United States.ORCID http://orcid.org/0000-0003-3573-3565
Salvatore La RosaChildren's Tumor Foundation, New York, NY, 10017, United States.
Sharad VermaDepartment of Neurology, The Johns Hopkins School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD, 21287, United States.
Lara MangraviteSage Bionetworks, Seattle, WA, 98146, United States.
Justin GuinneySage Bionetworks, Seattle, WA, 98146, United States.
Jaishri BlakeleyDepartment of Neurology, The Johns Hopkins School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD, 21287, United States.
Annette BakkerChildren's Tumor Foundation, New York, NY, 10017, United States.
Sara J C GoslineSage Bionetworks, Seattle, WA, 98146, United States. sara.gosline@sagebionetworks.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomedical ResearchInformation DisseminationNeurofibromatosesData CurationDatasets as TopicHumansResearch PersonnelStakeholder Participation

Identifiers

PMID31836719
PMCPMC6910996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.